KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Debt (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Total Debt for 16 consecutive years, with $16.8 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 5.49% year-over-year to $16.8 billion, compared with a TTM value of $16.8 billion through Dec 2025, down 5.49%, and an annual FY2025 reading of $16.8 billion, down 5.49% over the prior year.
  • Total Debt was $16.8 billion for Q4 2025 at Teva Pharmaceutical Industries, roughly flat from $16.8 billion in the prior quarter.
  • Across five years, Total Debt topped out at $25.1 billion in Q2 2021 and bottomed at $16.7 billion in Q1 2025.
  • Average Total Debt over 5 years is $20.4 billion, with a median of $20.3 billion recorded in 2023.
  • The sharpest move saw Total Debt dropped 4.28% in 2021, then fell 15.24% in 2025.
  • Year by year, Total Debt stood at $23.0 billion in 2021, then fell by 7.95% to $21.2 billion in 2022, then decreased by 6.5% to $19.8 billion in 2023, then decreased by 10.34% to $17.8 billion in 2024, then decreased by 5.49% to $16.8 billion in 2025.
  • Business Quant data shows Total Debt for TEVA at $16.8 billion in Q4 2025, $16.8 billion in Q3 2025, and $17.2 billion in Q2 2025.